Abstract
Objective:
The purpose of this study was to examine the hypothesis that angiotensin II (Ang II) induced endothelial cyclooxygenase-2 (COX-2) expression, which in turn mediated the generation of proinflammatory cytokines.
Methods and results:
Western blot analysis on primary rat endothelial cells showed Ang II induced COX-2 expression, which was abolished by cotreatment of p38 mitogen-activated protein kinase (SB 202190) and extracellular signal-regulated kinase 1/2 (PD 98059) inhibitors. Protein kinase Cδ (PKCδ) inhibitor (rottlerin) prevented extracellular signal-regulated kinase 1/2 phosphorylation and COX-2 expression. The pivotal role of PKCδ was further supported by a similar stimulatory effect of the PKC activator on COX-2 expression, signified by Ang II-stimulated translocation of PKCδ to the plasma membrane, and confirmed by PKCδ phosphorylation at Tyr311. Small interfering RNA targeting PKCδ diminished COX-2 expression, which was further abrogated by SB 202190. Human mesenteric arteries incubated with Ang II showed increased levels of endothelial COX-2 and monocyte chemoattractant protein-1; the former was inhibited by SB 202190 plus rottlerin, whereas the latter was prevented by COX-2 inhibitor.
Conclusions:
The present study pinpoints a novel role of PKCδ in Ang II-induced endothelial COX-2 upregulation and identifies a COX-2-dependent proatherosclerotic cytokine monocyte chemoattractant protein-1. The findings raise the possibility of curtailing endothelial COX-2 expression as a means of limiting or preventing vascular inflammation.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Aged, 80 and over
-
Angiotensin II / administration & dosage
-
Angiotensin II / metabolism*
-
Angiotensin II Type 1 Receptor Blockers / pharmacology
-
Animals
-
Atherosclerosis / enzymology*
-
Blotting, Western
-
Cells, Cultured
-
Chemokine CCL2 / metabolism
-
Cyclooxygenase 2 / metabolism*
-
Cyclooxygenase 2 Inhibitors / pharmacology
-
Disease Models, Animal
-
Endothelial Cells / drug effects
-
Endothelial Cells / enzymology*
-
Extracellular Signal-Regulated MAP Kinases / antagonists & inhibitors
-
Extracellular Signal-Regulated MAP Kinases / metabolism
-
Humans
-
Hypertension / chemically induced
-
Hypertension / enzymology
-
Hypertension / physiopathology
-
Hypertension / prevention & control
-
Inflammation / enzymology*
-
Inflammation Mediators / metabolism
-
Male
-
Mesenteric Arteries / drug effects
-
Mesenteric Arteries / enzymology*
-
Middle Aged
-
Phosphorylation
-
Protein Kinase C-delta / antagonists & inhibitors
-
Protein Kinase C-delta / genetics
-
Protein Kinase C-delta / metabolism*
-
Protein Kinase Inhibitors / pharmacology
-
Protein Transport
-
RNA Interference
-
Rats
-
Rats, Sprague-Dawley
-
Reactive Oxygen Species / metabolism
-
Receptor, Angiotensin, Type 1 / metabolism
-
Signal Transduction
-
Time Factors
-
Tissue Culture Techniques
-
Up-Regulation
-
p38 Mitogen-Activated Protein Kinases / antagonists & inhibitors
-
p38 Mitogen-Activated Protein Kinases / metabolism
Substances
-
Angiotensin II Type 1 Receptor Blockers
-
CCL2 protein, human
-
Chemokine CCL2
-
Cyclooxygenase 2 Inhibitors
-
Inflammation Mediators
-
Protein Kinase Inhibitors
-
Reactive Oxygen Species
-
Receptor, Angiotensin, Type 1
-
Angiotensin II
-
Cyclooxygenase 2
-
PTGS2 protein, human
-
Ptgs2 protein, rat
-
Prkcd protein, rat
-
PRKCD protein, human
-
Protein Kinase C-delta
-
Extracellular Signal-Regulated MAP Kinases
-
p38 Mitogen-Activated Protein Kinases